Cardiology

Ventricular Tachycardia

Questions discussed in this category

What is your preferred pharmacologic agent for recurrent VT suppression in arrhythmogenic right ventricular cardiomyopathy?

1 Answer available

Papers discussed in this category

Heart rhythm, 2019-11

2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy.

Heart Rhythm, 2015 Sep 30

Nadolol decreases the incidence and severity of ventricular arrhythmias during exercise stress testing compared with β1-selective β-blockers in patients with catecholaminergic polymorphic ventricular tachycardia.

J Am Coll Cardiol, 2009 Aug 25

The year in review of clinical cardiac electrophysiology.

Circulation, 1992 Jul

Efficacy of antiarrhythmic drugs in patients with arrhythmogenic right ventricular disease. Results in patients with inducible and noninducible ventricular tachycardia.

Related Topics in Cardiology